CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently down 0.23% at lunch.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently down 0.69% at lunch.
The CSL Limited (ASX:CSL) share price jumped 3% on Wednesday after the global biopharmaceutical company released its 2018 financial results.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently up 0.09% at lunch.
CSL Limited (ASX:CSL) reported a $1.7 billion profit for 2018, up 28% year over year, and a final unfranked dividend of $US0.93 per share.
Here are the headlines from the S&P/ASX 200 (INDEXASX:XJO)(ASX:XJO) and Australian finance circles on Wednesday morning.
Australia’s share market, or the All Ordinaries Index (INDEXASX:XAO)(ASX:XAO), is currently up 0.34% at lunch.
Australian Foundation Investment Co. Ltd. (ASX:AFI), also known as AFIC, just reported its annual result for the financial year ended 30 June 2018.
Australia’s share market, or the All Ordinaries Index (INDEXASX: XAO)(ASX: XAO), is currently up 0.38% at lunch.
